Extended Data Table 3 Part B – Plasma pharmacokinetics of nusinersen

From: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

  1. Analyses excluded participants who were missing any samples at pre-dose and at 2, 4, 8 or 24 hours post-dose after outlier exclusions.
  2. AUC0–24, area under the concentration–time curve from 1 to 24 hours; SMA, spinal muscular atrophy.
Back to article page